Critical Limb Ischemia - Pipeline Review, H2 2015 Is

Released
Critical Limb Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Critical Limb
Ischemia - Pipeline Review, H2 2015, provides an overview of the Critical Limb Ischemias therapeutic
pipeline. This report provides comprehensive information on the therapeutic development for Critical
Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest
updates, and featured news and press releases. It also reviews key players involved in the therapeutic
development for Critical Limb Ischemia and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser
based alert-box and clinical trials registries tracking ensure that the most recent developments are
captured on a real time basis. The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of data for the indicated
disease. Scope - The report provides a snapshot of the global therapeutic landscape of Critical Limb
Ischemia - The report reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Critical Limb Ischemia and
enlists all their major and minor projects - The report summarizes all the dormant and discontinued
pipeline projects - A review of the Critical Limb Ischemia products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the Critical Limb Ischemia pipeline on the basis of
target, MoA, route of administration and molecule type - Latest news and deals relating related to
pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Critical
Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most
promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb
Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and

expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173371/critical-limbischemia-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173371/critical-limb-ischemia-pipeline-review-h2-2015

Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Critical Limb Ischemia Overview 10
Therapeutics Development 11
Pipeline Products for Critical Limb Ischemia - Overview 11
Pipeline Products for Critical Limb Ischemia - Comparative Analysis 12
Critical Limb Ischemia - Therapeutics under Development by Companies 13
Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 15
Critical Limb Ischemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Critical Limb Ischemia - Products under Development by Companies 19
Critical Limb Ischemia - Products under Investigation by Universities/Institutes 21
Critical Limb Ischemia - Companies Involved in Therapeutics Development 22
AnGes MG, Inc. 22
Apceth GmbH & Co. KG 23
Athersys, Inc. 24
Caladrius Biosciences, Inc. 25
Cynata Therapeutics Limited 26
2

DNAVEC Corporation 27
Hemostemix Ltd 28
IntelliCell BioSciences Inc. 29
Juventas Therapeutics, Inc. 30
Kasiak Research Private Limited 31
Multi Gene Vascular Systems Ltd 32
Pharmicell Co., Ltd. 33
Pluristem Therapeutics Inc. 34
ReNeuron Group Plc 35
Stempeutics Research Private Limited 36
Targazyme, Inc. 37
TikoMed AB 38
U.S. Stem Cell, Inc. 39
Vericel Corporation 40
ViroMed Co., Ltd. 41
Critical Limb Ischemia - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
ACP-01 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AdipoCell - Drug Profile 53
3

Product Description 53
Mechanism of Action 53
R&D Progress 53
Alecmestencel-T - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ASCT-01 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Autologous Vascular Cells Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
beperminogene perplasmid - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cell Therapy for Critical Limb Ischemia - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cellgram for Severe Lower Limb Ischemia - Drug Profile 64
Product Description 64
Mechanism of Action 64

R&D Progress 64
CLBS-12 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DVC1-0101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ixmyelocel-T - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JVS-100 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MultiGeneAngio - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MultiStem - Drug Profile 76
Product Description 76
5

Mechanism of Action 76
R&D Progress 76
PLX-PAD - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Recombinant Protein for Critical Limb Ischemia - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Refacell-CLI - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Rejuveinix - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ReN-009 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88

Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 89

Product Description 89
Mechanism of Action 89
R&D Progress 89
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Stempeucel - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
TM-700 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TZ-101 - Drug Profile 97
Product Description 97
Mechanism of Action 97
7

R&D Progress 97
VM-202 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Critical Limb Ischemia - Recent Pipeline Updates 101
Critical Limb Ischemia - Dormant Projects 129
Critical Limb Ischemia - Discontinued Products 130
Critical Limb Ischemia - Product Development Milestones 131
Featured News & Press Releases 131
Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa 131
Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2
Clinical Trial to Taiwan 131
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy
in a Range of Indications 132
Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene
Therapy for Critical Limb Ischemia 132
Aug 12, 2015: Japan Grants Safety Clearance to Pluristems PLX-PAD Cells for Use in Clinical Trials 133
Aug 10, 2015: Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in
the United States 133
Jul 27, 2015: Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for
Critical Limb Ischemia 133
Jun 25, 2015: Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase2 Clinical Trial for Critical Limb Ischemia 134
Jun 18, 2015: Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and
Drug Administration for Companys ACP-01 Formulation to Treat Critical Limb Ischemia 134
Jun 08, 2015: Stempeutics receives Japan process patent for its novel stem cell drug, Stempeucel 135
Appendix 136
Methodology 136
Coverage 136
8

Secondary Research 136

Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173371/critical-limbischemia-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects

10